查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1606412

去勢抵抗性前列腺市場，按治療方法、配銷通路、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Castrate Resistant Prostate Market, By Therapy, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 260 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年，去勢抵抗性攝護腺市場價值為89.0454億美元，2024年至2032年複合年成長率為8.70%。

去勢抵抗性前列腺市場-市場動態

增加前列腺癌的早期檢測預計將推動市場成長。

早期檢測有助於在前列腺癌的初始階段透過雄性激素剝奪療法 (ADT) 或替代療法進行及時干預。然而，儘管進行了初步治療，某些病例仍會進展為去勢抵抗性前列腺癌（CRPC），但早期干預可能有助於延長患者的生存期。雖然前列腺癌可能帶來重大的健康風險，但大多數被診斷出患有疾病的男性並沒有屈服於這種疾病。根據美國癌症協會預測，2024 年美國前列腺癌新發病例約為 299,010 例，約 35,250 人因該疾病死亡。此外，新療法的出現和診斷技術的進步可能會為市場擴張開闢新的途徑。然而，發展中地區的意識和診斷能力有限可能會阻礙市場成長。

去勢抵抗性前列腺市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032 年）每年將以 8.70% 左右的複合年成長率成長

根據治療細分，荷爾蒙療法是 2023 年領先的藥物類別

按地區分類，北美是 2023 年的主要收入來源

去勢抵抗性前列腺市場-細分分析：

全球去勢抵抗性前列腺市場根據治療、配銷通路和地區進行細分。

根據治療類型，市場分為四個不同的類別：化療、荷爾蒙治療、免疫療法和放射治療。荷爾蒙療法在市場上佔據主導地位。鑑於前列腺癌的進展主要受雄激素，特別是睾酮的影響，這種治療形式對於去勢抵抗性前列腺癌（CRPC）的治療至關重要。

根據配銷通路，市場分為四類：醫院、癌症治療中心、零售藥房和線上藥房。醫院和癌症治療中心在提供先進和專業護理方面繼續發揮至關重要的作用，而隨著越來越多的患者選擇門診治療管理，零售和線上藥局也變得越來越重要。

去勢抵抗性前列腺市場 - 地理洞察

市場地域廣闊，涵蓋北美、拉丁美洲、歐洲、亞太地區、中東和非洲。這些領域根據對商業活動做出貢獻的國家進一步分類。北美在市場擴張方面處於領先地位，這主要是由於醫療保健支出的增加和治療選擇的增加。北美地區，尤其是美國和加拿大醫療保健支出的大幅成長對 CRPC 市場的成長至關重要。醫療保健預算的增加促進了對最先進的醫療、先進的診斷工具和 CRPC 創新療法的更多投資。根據國家衛生支出，2022 年美國醫療保健支出成長 4.1%，達到 4.5 兆美元，超過 2021 年 3.2% 的增幅，但仍遠低於 2020 年 10.6% 的增幅。了市場成長的最大區域。

去勢抵抗性前列腺市場-競爭格局：

去勢抵抗性前列腺癌 (CRPC) 市場的特點是致力於創新療法開發和商業化的製藥和生物製藥公司之間的激烈競爭。由於已有多種成熟的治療方法，市場正在經歷日益飽和，促使公司採取積極的行銷和促銷策略來獲得更大的佔有率。對聯合療法、基因分析和免疫腫瘤學的重視預計將進一步影響不斷變化的競爭環境。

最新進展：

2019 年9 月30 日，《新英格蘭醫學雜誌》發布的研究結果表明，患有轉移性去勢抵抗性前列腺癌(mCRPC) 的患者先前接受過多西他賽治療，並在接受雄激素受體(AR) 治療期間在12 個月內出現疾病進展）標靶治療（阿比特龍或恩雜魯胺）與接受阿比特龍加潑尼鬆或恩雜魯胺治療的患者相比，使用Jevtana（卡巴他賽）合併潑尼松治療時，影像學無惡化存活期(rPFS) 顯著延長。

2024 年1 月24 日，強生公司透露，新的臨床和現實世界證據將在即將於1 月25 日至27 日在舊金山舉行的ASCO GU 研討會上以18 份摘要的形式提出。本公司的奉獻精神推進泌尿生殖 (GU) 癌症的研究。

目錄

第1章：去勢抵抗性前列腺市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 去勢抵抗性前列腺治療市場片段
    • 按配銷通路分類的去勢抵抗性前列腺市場片段
    • 去勢抗性前列腺市場片段（依國家/地區）
    • 按地區分類的去勢抗性前列腺市場片段
  • 競爭洞察

第 3 章：去勢抵抗性攝護腺主要市場趨勢

  • 去勢抵抗性前列腺市場促進因素
    • 市場促進因素的影響分析
  • 去勢抵抗性前列腺市場的限制
    • 市場限制影響分析
  • 去勢抵抗性前列腺市場機會
  • 去勢抵抗性前列腺市場未來趨勢

第 4 章：去勢抗性前列腺產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：去勢抵抗性前列腺市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：去勢抵抗性前列腺市場格局

  • 2022 年抗去勢前列腺市場佔有率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：去勢抵抗性前列腺市場 - 透過治療

  • 概述
    • 按療法分類的細分市場佔有率分析
    • 化療
    • 荷爾蒙療法
    • 免疫治療
    • 放射治療

第 8 章：去勢抵抗性前列腺市場 - 按配銷通路

  • 概述
    • 按配銷通路分類的細分市場佔有率分析
    • 醫院
    • 癌症治療中心
    • 零售藥局
    • 網路藥局

第 9 章：去勢抵抗性前列腺市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美抗去勢前列腺主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按治療）
    • 北美市場規模和預測（按配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲抗去勢前列腺主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模與預測（按治療）
    • 歐洲市場規模和預測（按配銷通路）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區抗去勢前列腺主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模與預測（按治療）
    • 亞太地區市場規模和預測（按配銷通路）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲抗去勢攝護腺主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按療法）
    • 拉丁美洲市場規模和預測（按配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲去勢抗性前列腺主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模和預測（按療法）
    • 中東和非洲市場規模及預測（按配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 10 章：主要供應商分析 - 抗去勢前列腺產業

  • 競爭儀表板
  • 公司簡介
    • Sanofi
    • Johnson & Johnson Services, Inc.
    • Pfizer, Inc.
    • Astellas Pharma, Inc.
    • Bayer AG
    • Phinergy
    • Others

第 11 章：360 度分析師視角

第 12 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4182

REPORT HIGHLIGHT

The Castrate-Resistant Prostate Market was valued at USD 8,904.54 million in 2023 and expanded at a CAGR of 8.70% from 2024 to 2032.

Castration-resistant prostate cancer (CRPC) represents an advanced stage of prostate cancer. In cases of CRPC, the cancer exhibits limited responsiveness to therapies aimed at reducing testosterone levels. Indicators of progression, such as an increasing prostate-specific antigen (PSA) level, can occur despite diminished testosterone. Generally, CRPC is associated with a less favorable prognosis than hormone-sensitive prostate cancer, as it tends to be more aggressive and prone to metastasis. Current research efforts are directed toward elucidating the mechanisms underlying resistance to androgen deprivation and creating innovative treatment options that target these pathways.

Castrate Resistant Prostate Market- Market Dynamics

Increasing early detection of prostate cancer is expected to propel market growth.

Early detection facilitates prompt intervention through androgen deprivation therapies (ADT) or alternative treatments during the initial stages of prostate cancer. Nevertheless, certain cases will progress to castration-resistant prostate cancer (CRPC) despite initial therapies, yet early intervention may contribute to prolonged patient survival. While prostate cancer can pose significant health risks, the majority of men diagnosed with the disease do not succumb to it. According to the American Cancer Society, projections for prostate cancer in the United States for 2024 indicate approximately 299,010 new cases and around 35,250 fatalities attributed to the disease. Additionally, the emergence of novel therapies and advancements in diagnostic technologies may open new pathways for market expansion. However, limited awareness and diagnostic capabilities in developing regions could hinder market growth.

Castrate Resistant Prostate Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.70% over the forecast period (2024-2032)

Based on Therapy segmentation, Hormonal Therapy was the leading Drug Class in 2023

Based on region, North America was the leading revenue generator in 2023

Castrate Resistant Prostate Market- Segmentation Analysis:

The Global Castrate Resistant Prostate Market is segmented based on Therapy, Distribution channel, and Region.

The market is segmented into four distinct categories according to therapy type: Chemotherapy, Hormonal Therapy, Immunotherapy, and Radiotherapy. Hormonal Therapy holds a predominant position in the market. This form of therapy is essential in the management of Castrate-Resistant Prostate Cancer (CRPC), given that the progression of prostate cancer is primarily influenced by androgen hormones, particularly testosterone.

The market is segmented into four categories according to the Distribution Channel: Hospitals, Cancer Treatment Centers, Retail Pharmacies, and Online Pharmacies. Hospitals and cancer treatment centers continue to play a vital role in delivering advanced and specialized care, whereas retail and online pharmacies are increasingly significant as a growing number of patients opt for outpatient treatment management.

Castrate Resistant Prostate Market- Geographical Insights

This market is geographically extensive, encompassing North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These areas are further categorized based on the countries contributing to business activities. North America leads in market expansion, primarily due to rising healthcare expenditures and enhanced access to treatment options. The significant increase in healthcare spending in North America, especially in the United States and Canada, is crucial to the growth of the CRPC market. Elevated healthcare budgets facilitate greater investment in state-of-the-art medical treatments, advanced diagnostic tools, and innovative therapies for CRPC. According to National Health Expenditures, healthcare spending in the U.S. rose by 4.1% to USD 4.5 trillion in 2022, outpacing the 3.2% increase observed in 2021, although it remains considerably lower than the 10.6% surge in 2020. Europe ranks as the second-largest region for market growth, driven by a growing preference for outpatient care.

Castrate Resistant Prostate Market- Competitive Landscape:

The market for castrate-resistant prostate cancer (CRPC) is marked by significant competition among pharmaceutical and biopharmaceutical companies dedicated to the development and commercialization of innovative therapies. As numerous established treatments are already present, the market is experiencing a growing saturation, prompting companies to engage in vigorous marketing and promotional strategies to secure a larger share. The emphasis on combination therapies, genetic profiling, and immuno-oncology is expected to further influence the evolving competitive environment.

Recent Developments:

On September 30, 2019, findings released in the New England Journal of Medicine indicated that patients suffering from metastatic castration-resistant prostate cancer (mCRPC) who had previously undergone treatment with docetaxel and exhibited disease progression within 12 months while on an androgen receptor (AR)-targeted therapy (either abiraterone or enzalutamide) demonstrated a notably extended radiographic progression-free survival (rPFS) when treated with Jevtana (cabazitaxel) in combination with prednisone, in comparison to those receiving abiraterone plus prednisone or enzalutamide.

On January 24, 2024, Johnson & Johnson revealed that new clinical and real-world evidence will be presented in 18 abstracts at the upcoming ASCO GU Symposium, scheduled to take place in San Francisco from January 25 to 27. This announcement underscores the Company's dedication to advancing the research in genitourinary (GU) cancers.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CASTRATE-RESISTANT PROSTATE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Sanofi
  • Johnson & Johnson Services, Inc.
  • Pfizer, Inc.
  • Astellas Pharma, Inc.
  • Bayer AG
  • Phinergy
  • Others

GLOBAL CASTRATE RESISTANT PROSTATE MARKET, BY THERAPY- MARKET ANALYSIS, 2019 - 2032

  • Chemotherapy
  • Hormonal Therapy
  • Immunotherapy
  • Radiotherapy

GLOBAL CASTRATE RESISTANT PROSTATE MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Cancer Treatment Centers
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL CASTRATE RESISTANT PROSTATE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Castrate Resistant Prostate Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Castrate Resistant Prostate Market Snippet by Therapy
    • 2.1.2. Castrate Resistant Prostate Market Snippet by Distribution Channel
    • 2.1.3. Castrate Resistant Prostate Market Snippet by Country
    • 2.1.4. Castrate Resistant Prostate Market Snippet by Region
  • 2.2. Competitive Insights

3. Castrate Resistant Prostate Key Market Trends

  • 3.1. Castrate Resistant Prostate Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Castrate Resistant Prostate Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Castrate Resistant Prostate Market Opportunities
  • 3.4. Castrate Resistant Prostate Market Future Trends

4. Castrate Resistant Prostate Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Castrate Resistant Prostate Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Castrate Resistant Prostate Market Landscape

  • 6.1. Castrate Resistant Prostate Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Castrate Resistant Prostate Market - By Therapy

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapy, 2022 & 2030 (%)
    • 7.1.2. Chemotherapy
    • 7.1.3. Hormonal Therapy
    • 7.1.4. Immunotherapy
    • 7.1.5. Radiotherapy

8. Castrate Resistant Prostate Market - By Distribution Channel

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
    • 8.1.2. Hospitals
    • 8.1.3. Cancer Treatment Centers
    • 8.1.4. Retail Pharmacies
    • 8.1.5. Online Pharmacies

9. Castrate Resistant Prostate Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Castrate Resistant Prostate Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Castrate Resistant Prostate Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Castrate Resistant Prostate Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Castrate Resistant Prostate Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Castrate Resistant Prostate Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

10. Key Vendor Analysis- Castrate Resistant Prostate Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Sanofi
    • 10.2.2. Johnson & Johnson Services, Inc.
    • 10.2.3. Pfizer, Inc.
    • 10.2.4. Astellas Pharma, Inc.
    • 10.2.5. Bayer AG
    • 10.2.6. Phinergy
    • 10.2.7. Others

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us